An exciting new national study of prostate cancer specific to African Americans has been launched to assess risk factors associated with this group of men and why a higher rate of aggressive disease exists. This study is the first of its kind and researchers hope to uncover targeted treatment strategies for African Americans as a result. Dr. Damali N. Martin introduced this study and provides details on the disparity in prostate cancer burden that exists based on race with data sourced from the National Cancer Institute, where she serves as program director. Dr. Franklin Huang, a principal investigator for the study, covers biological reasons why this group of men is more likely to be diagnosed with the disease. He also outlines the goals of the RESPONDtrial and provides details on taking part in the study.
Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint
A new treatment for prostate cancer patients looks to be on the horizon as the ARAMIS clinical trial has succeeded in meeting its primary objective, and Bayer has announced that it is moving forward with the steps necessary to bring Darolutamide to patients. ARAMIS was among the initial group of trials included with the launch of PHEN's Clinical Trials Rally.....Read more
Rubraca's Positive Results Lead to Advancement by FDA
Rubraca (rucaparib) received a vote of confidence from the FDA, as the drug already approved to treat ovarian cancer was awarded a breakthrough designation to accelerate its review for approval in a new use for prostate cancer. This was the result of positive initial data from the TRITON2 clinical trial sponsored by Clovis Oncology.
About Clinical Trials Benefits.....
40% of people do not understand the idea of a clinical trial, according to a survey done by the Journal of Clinical Oncology. This lack of knowledge about clinical trials negatively affects the likelihood of patients to enroll in a study, and take advantage of the possible Clinical Trials benefits.
For more information about Clinical Trials, please email Dr. Arash Eshraghi, PHEN's Clinical Trials Rally Coordinator at firstname.lastname@example.org